At the news
? NEUTRALIMPACT 5/10 8-K filed Apr 2, 2026 at 08:34 ET
Palisade Bio issued 1.54 million shares to an affiliate of Iterative Health for $3.0 million to support a clinical trial partnership for its ulcerative colitis drug PALI-2108. The company also entered into a master services agreement with Iterative Health to accelerate patient enrollment in the upcoming Phase 2 study.
- Palisade Bio issued 1,536,885 shares of common stock to an affiliate of Iterative Health for $3.0 million ($1.952 per share)
- Proceeds support collaboration with Iterative Health to expedite patient enrollment in the Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis
- The share issuance was conducted under a private placement exempt from registration under Section 4(a)(2) of the Securities Act
- The transaction represents approximately 4.9% of Palisade Bio's current market cap of $312M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access